GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (STU:A71) » Definitions » Cyclically Adjusted Price-to-FCF

Ascendis Pharma A/S (STU:A71) Cyclically Adjusted Price-to-FCF : (As of Jun. 02, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF falls into.



Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Ascendis Pharma A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ascendis Pharma A/S's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.789/118.4000*118.4000
=-1.789

Current CPI (Mar. 2024) = 118.4000.

Ascendis Pharma A/S Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.464 99.700 -0.551
201409 -0.203 99.700 -0.241
201412 -0.454 99.400 -0.541
201503 -0.296 100.200 -0.350
201506 -0.602 100.300 -0.711
201509 -0.510 100.200 -0.603
201512 -0.412 99.800 -0.489
201603 -0.598 100.200 -0.707
201606 -0.519 100.600 -0.611
201609 -0.635 100.200 -0.750
201612 -0.545 100.300 -0.643
201703 -0.667 101.200 -0.780
201706 -0.742 101.200 -0.868
201709 -0.794 101.800 -0.923
201712 -0.660 101.300 -0.771
201803 -0.952 101.700 -1.108
201806 -0.491 102.300 -0.568
201809 -1.135 102.400 -1.312
201812 -0.871 102.100 -1.010
201903 -1.460 102.900 -1.680
201906 -0.131 102.900 -0.151
201909 -1.286 102.900 -1.480
201912 -1.053 102.900 -1.212
202003 -1.520 103.300 -1.742
202006 -1.276 103.200 -1.464
202009 -1.197 103.500 -1.369
202012 -1.785 103.400 -2.044
202103 -1.603 104.300 -1.820
202106 -2.206 105.000 -2.488
202109 -1.992 105.800 -2.229
202112 -2.254 106.600 -2.504
202203 -2.373 109.900 -2.557
202206 -2.296 113.600 -2.393
202209 -1.827 116.400 -1.858
202212 -2.600 115.900 -2.656
202303 -2.641 117.300 -2.666
202306 -2.732 116.400 -2.779
202309 -2.234 117.400 -2.253
202312 -0.750 116.700 -0.761
202403 -1.789 118.400 -1.789

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma A/S  (STU:A71) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (STU:A71) Business Description

Industry
Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (STU:A71) Headlines

No Headlines